<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0"
	xmlns:content="http://purl.org/rss/1.0/modules/content/"
	xmlns:wfw="http://wellformedweb.org/CommentAPI/"
	xmlns:dc="http://purl.org/dc/elements/1.1/"
	xmlns:atom="http://www.w3.org/2005/Atom"
	xmlns:sy="http://purl.org/rss/1.0/modules/syndication/"
	xmlns:slash="http://purl.org/rss/1.0/modules/slash/"
	>

<channel>
	<title>PILMAN &#187; Vitrakvi</title>
	<atom:link href="http://www.tapanray.in/tag/vitrakvi/feed/" rel="self" type="application/rss+xml" />
	<link>http://www.tapanray.in</link>
	<description>A Tapan Ray Website</description>
	<lastBuildDate>Sun, 22 Mar 2026 10:59:18 +0000</lastBuildDate>
	<language>en-US</language>
	<sy:updatePeriod>hourly</sy:updatePeriod>
	<sy:updateFrequency>1</sy:updateFrequency>
	<generator>http://wordpress.org/?v=3.4.2</generator>
		<item>
		<title>Pharma’s Oncology Focus: Some Key Drivers With Pros And Cons For Patients</title>
		<link>http://www.tapanray.in/pharmas-oncology-focus-some-key-drivers-with-pros-and-cons-for-patients/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=pharmas-oncology-focus-some-key-drivers-with-pros-and-cons-for-patients</link>
		<comments>http://www.tapanray.in/pharmas-oncology-focus-some-key-drivers-with-pros-and-cons-for-patients/#comments</comments>
		<pubDate>Mon, 28 Jan 2019 00:00:03 +0000</pubDate>
		<dc:creator>Tapan Ray</dc:creator>
				<category><![CDATA[Pharma]]></category>
		<category><![CDATA[acquisition]]></category>
		<category><![CDATA[Affordability]]></category>
		<category><![CDATA[Bristol]]></category>
		<category><![CDATA[Bristol-Myers Squibb]]></category>
		<category><![CDATA[cancer]]></category>
		<category><![CDATA[Celgene]]></category>
		<category><![CDATA[cons]]></category>
		<category><![CDATA[drivers]]></category>
		<category><![CDATA[focus]]></category>
		<category><![CDATA[India]]></category>
		<category><![CDATA[M&A]]></category>
		<category><![CDATA[Myers]]></category>
		<category><![CDATA[oncology]]></category>
		<category><![CDATA[Patients]]></category>
		<category><![CDATA[price]]></category>
		<category><![CDATA[pros]]></category>
		<category><![CDATA[strategy]]></category>
		<category><![CDATA[TRK inhibitor]]></category>
		<category><![CDATA[Vitrakvi]]></category>

		<guid isPermaLink="false">http://www.tapanray.in/?p=9391</guid>
		<description><![CDATA[Just in the first ten days of the brand-new year &#8211; 2019, three important oncology focused acquisitions were announced by three top global pharma companies. On January 03, 2019, Bristol-Myers Squibb announced that it will acquire Celgene for a hefty sum of USD &#8230; <a href="http://www.tapanray.in/pharmas-oncology-focus-some-key-drivers-with-pros-and-cons-for-patients/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
		<wfw:commentRss>http://www.tapanray.in/pharmas-oncology-focus-some-key-drivers-with-pros-and-cons-for-patients/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
	</channel>
</rss>
